Summary of Study ST004035
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002527. The data can be accessed directly via it's Project DOI: 10.21228/M80R9W This work is supported by NIH grant, U2C- DK119886. See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST004035 |
| Study Title | Serum Metabolites at Defined Stages of Liver Disease |
| Study Summary | The goal of this study was to reveal serum metabolome differences at defined stages of liver disease from fatty liver to hepatocellular carcinoma. This study investigates serum metabolomic alterations in a mouse model of non-alcoholic steatohepatitis (NASH) and HCC) using the STAM (Streptozotocin and High-Fat Diet) model. Male mice were administered streptozotocin (STZ) shortly after birth and subsequently fed a high-fat diet to induce liver disease progression resembling human NASH and HCC. Blood samples were collected at a defined disease stage , and serum was isolated for untargeted metabolomic profiling. Using LC-MS, we profiled the serum metabolites to identify disease-associated metabolic signatures. The study parameters include treatment condition (control vs. STAM), sample collection time (e.g., ZT8), and serum metabolite intensity values. Analysis revealed significant changes in pathways related to lipid metabolism, bile acid biosynthesis, amino acid metabolism, and energy homeostasis in the STAM group compared to controls. These metabolic alterations may reflect the systemic metabolic disturbances associated with NASH progression and HCC risk, providing potential biomarkers and therapeutic targets. |
| Institute | University of Texas Health Science Center at Houston |
| Department | IMM |
| Laboratory | Mahan Lab |
| Last Name | Fekry |
| First Name | Baharan |
| Address | The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), 1825 Pressler St, Houston TX 77030, USA. |
| Baharan.Fekry@uth.tmc.edu | |
| Phone | 18434693199 |
| Submit Date | 2025-07-02 |
| Analysis Type Detail | LC-MS |
| Release Date | 2025-07-15 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002527 |
| Project DOI: | doi: 10.21228/M80R9W |
| Project Title: | Serum Metabolites at Defined Stages of Liver Disease |
| Project Summary: | The present dataset comprises a total of 978 compounds of known identity (named biochemicals). Following log transformation and imputation of missing values, if any, with the minimum observed value for each compound, ANOVA contrasts were used to identify biochemicals that differed significantly between experimental groups. A summary of the numbers of biochemicals that achieved statistical significance (p≤0.05), as well as those approaching significance (0.05<p<0.10), is shown below. Analysis by two-way ANOVA identified biochemicals exhibiting significant interaction and main effects for experimental parameters of time and treatment. An estimate of the false discovery rate (q-value) is calculated to take into account the multiple comparisons that normally occur in metabolomic-based studies. For example, when analyzing 200 compounds, we would expect to see about 10 compounds meeting the p≤0.05 cut-off by random chance. The q-value describes the false discovery rate; a low q-value (q<0.10) is an indication of high confidence in a result. While a higher q-value indicates diminished confidence, it does not necessarily rule out the significance of a result. Other lines of evidence may be taken into consideration when determining whether a result merits further scrutiny. Such evidence may include a) significance in another dimension of the study, b) inclusion in a common pathway with a highly significant compound, or c) residing in a similar functional biochemical family with other significant compounds. Refer to the Appendix for general definitions and further descriptions of false discovery rate and other statistical tests used at Metabolon. |
| Institute: | University of Texas Health Science Center at Houston |
| Department: | IMM |
| Laboratory: | Mahan Lab |
| Last Name: | Fekry |
| First Name: | Baharan |
| Address: | The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (IMM), 1825 Pressler St, Houston TX 77030. USA. |
| Email: | Baharan.Fekry@uth.tmc.edu |
| Phone: | 8434693199 |
